Latest Market Entry News

Osteopore Limited has secured an exclusive three-year distribution deal with Medprin Biotech GmbH to broaden its presence in Latin America's craniofacial reconstruction market, tapping into a region poised for significant growth.

Temple & Webster Group Limited reported a robust 20% revenue increase to $376 million in the first half of FY26, maintaining momentum towards its $1 billion revenue target by FY28. The company’s strategic investments in AI, exclusive products, and new markets like New Zealand underpin its expanding market presence.

Temple & Webster has reported a robust 20% increase in half-year revenue to $376 million, expanding its market share and launching successfully into New Zealand. EBITDA remains within guidance despite new market investments.

Temple & Webster reported a 20% revenue increase to $375.9 million for H1 FY26, driven by record active customers and exclusive product growth. However, profit before tax fell 25% to $9.4 million, impacted by investments in New Zealand and higher marketing spend.

Janus Electric has landed further orders worth approximately A$1.6 million from its authorised California dealer, Electric Vehicle Choice, marking a significant step in its U.S. market expansion. The orders include conversion modules, batteries, and charging infrastructure, with shipment planned for mid-2026.

CSL Limited has released its half-year results showing a slight revenue decline amid ongoing transformation efforts, while maintaining its full-year guidance and expanding its share buyback program.

Imricor Medical Systems has taken a significant step toward US market entry by submitting its Advantage-MR EP Recorder/Stimulator system for FDA 510(k) clearance, aiming to enhance MRI-guided cardiac procedures.

Prairie Lithium has retracted its previous production target citing compliance issues, while announcing a binding offtake agreement with South Korea’s Hydro Lithium for its Phase 1 lithium output. This move signals a strategic shift towards selling intermediate lithium products to reduce costs and accelerate market entry.

GCM Corporation is advancing its commercialisation strategy with multiple prototypes across key global markets and sectors, aiming for revenue in the first half of 2026.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

Credit Corp Group Limited reported a steady half-year profit with a 4% revenue rise, driven by strong US collections and record lending volumes, while advancing its UK presence through a strategic acquisition.